Feature | March 27, 2015

Heart Failure Patients Fare Better with Catheter Ablation than Amiodarone

Catheter ablation significantly more effective at eliminating atrial fibrillation

catheter ablation, Afib, Amiodarone, Luigi Di Biase, ACC, heart failure

March 27, 2015 — Patients with heart failure and atrial fibrillation were less likely to experience death, hospitalization or recurrent Afib with catheter ablation than with a heart rhythm-regulating drug, according to a new study. Catheter ablation was most successful in procedures where ablation was required in other areas in addition to the pulmonary vein. The study was presented at the American College of Cardiology’s 64th Annual Scientific Session.

Heart failure and atrial fibrillation often co-occur and are two of the most common heart problems in older adults. In the new study, 71 percent of patients treated with surgical catheter ablation were free of atrial fibrillation, the study’s primary endpoint, after two years of follow-up; only 34 percent of patients who took the anti-arrhythmic drug Amiodarone were free of symptoms at that point.

“Even when it is effective, Amiodarone often needs to be discontinued after a while due to serious long-term side effects,” said Luigi Di Biase, M.D., Ph.D., a cardiologist and electrophysiologist at St. David’s Medical Center and the Albert Einstein College of Medicine at Montefiore Hospital and the study’s lead author. “Our study suggests that in patients with heart failure and atrial fibrillation, catheter ablation is an effective alternative treatment that can help patients avoid or discontinue this drug to reduce the risk of these long-term side effects.”

About 5 million Americans have heart failure, and an estimated 5.6 million U.S. adults have Afib. Patients with both conditions are at especially high risk of serious complications and death. Amiodarone helps to regulate the heart’s rhythm in these patients by relaxing the heart muscle.

“It is very important to control persistent atrial fibrillation in patients with heart failure,” Di Biase said. “These patients need every bit of blood that the heart can pump, so it becomes particularly dangerous when an arrhythmia happens. People with both of these conditions frequently wind up in the hospital.”

The study included just over 200 patients treated in eight European and U.S. hospitals. All patients had heart failure, atrial fibrillation and either an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D), two medical devices that are commonly placed in patients with these conditions to control life-threatening arrhythmias or help the heart pump blood more effectively.

The researchers randomly assigned half of the patients to undergo catheter ablation, a surgical procedure in which doctors thread thin, flexible wires into the heart through blood vessels in the arm, groin or neck. These wires are used to deliver energy or heat that destroys the areas of heart tissue that cause the abnormal heart rhythm. The rest of the patients were treated with Amiodarone. In addition to having a higher rate of freedom from atrial fibrillation, participants who underwent catheter ablation also had lower rates of hospitalization and mortality during the two-year follow up. Thirty-one percent of patients receiving ablation were subsequently hospitalized compared to 57 percent of patients taking Amiodarone. Eight percent of patients receiving ablation died during the course of the study compared to 18 percent of patients taking Amiodarone. Di Biase said the type and extent of the ablation procedure had a marked impact on the procedure’s success rate.

“If the ablation is limited to the pulmonary vein alone, the success rate goes down—almost to the level of the Amiodarone treatment,” Di Biase said. “The highest success rates were for procedures in which other areas (in addition to the pulmonary vein) were ablated.”

The specific areas that benefit from additional ablation depend on each patient’s individual condition. In addition, many patients in the study required more than one ablation procedure to achieve freedom from atrial fibrillation.

Di Biase said another limitation of the study is that not all hospitals have the experience and equipment necessary to properly perform catheter ablation. As a result, the advantage of ablation over Amiodarone might not be as dramatic outside of top-tier hospitals. Further research would help to track the procedure’s effectiveness in a broader variety of circumstances.

There was no external funding for this study.

For more information: www.einstein.yu.edu

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init